Sermorelin

Drug Profile

Sermorelin

Alternative Names: Geref; Gerel; GRF 1-29; GRF(1-29)NH2; Groliberin; Growth hormone releasing factor-(1-29)amide; Human growth hormone releasing factor; human somatoliberin-(1-29) amide; Somatoliberin-(1-29) amide

Latest Information Update: 18 Jul 2014

Price : $50

At a glance

  • Originator Salk Institute
  • Class Growth hormone-releasing hormones; Peptide hormones
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Somatotropin deficiency
  • Discontinued Female infertility

Most Recent Events

  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top